Australian Dollar Forecast: Dovish RBA To Counterbalance Robust Chinese GDP Print

U.S. dollar banknote with map


  • The RBA’s semi-annual Financial Stability Review, and concerns surround AstraZeneca’s vaccine, may continue to drive the risk-sensitive AUD lower in the near term.
  • However, robust Chinese economic data may limit the currency’s potential downside, with Q1 GDP expected to reinforce the nation’s strong rebound in output.


The risk-sensitive Australian Dollar may continue to lose ground against its haven-associated counterparts in the week ahead despite the prospect of robust Chinese first-quarter GDP figures, as the Reserve Bank of Australia’s semi-annual Financial Stability Review reveals growing risks to the local economy.

The central bank warned that risky behaviour from overly-optimistic investors could drive asset prices above their fundamental values and cause debt levels to build, exposing these assets to a large correction that “would expose lenders to large losses on the increased debt, particularly if the quality of that debt had been eroded”.

However, the RBA downplayed the recent rise in housing prices as a threat to financial stability, as it had not been accompanied by a notable build up in debt. House prices surged by the largest amount since 1988, – on a monthly basis – in March, as record low interest rates and cheap mortgages continues to fuel demand.

Australian Dollar Forecast: Dovish RBA to Counterbalance Robust Chinese GDP Print

This commentary suggests that the central bank will retain its dovish monetary policy stance for the foreseeable future. Indeed, Governor Phillip Lowe has stated that the bank may roll over the November 2024 bond from the April 2024 bond for its YCC target in the coming months, and reiterated that “the bank is prepared to undertake further bond purchases if doing so would assist with progress towards the goals of full employment and inflation”.

Compounding the downside pressure on the local currency is the cumbersome rollout of coronavirus vaccines to the public, with only 1.07 million doses administered as of April 7. This is far short of the four million doses projected to have been delivered by now, and the rate of inoculations is unlikely to pick up given the recent warnings regarding AstraZeneca’s shot.

1 2
View single page >> |

Disclaimer: DailyFX, the free news and research website from IG, is one of the world's leading sources for news and analysis on the ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.